Opentrons vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Opentrons democratizes lab automation with 10,000+ OT-2 and Flex robotic systems deployed globally; raised $200M+ including $20M Series C in Nov 2025; partnered with BD and HighRes for AI agent-to-agent workflows.
About
Opentrons Labworks is a New York-based life sciences company that designs and manufactures affordable, open-source liquid-handling robots for research laboratories. Founded in 2014, Opentrons'' mission is to democratize biology by making advanced lab automation accessible to life scientists at any institution — from academic labs with limited budgets to leading pharmaceutical companies. Its flagship products, the OT-2 and the newer Opentrons Flex, are programmable robotic platforms that automate repetitive liquid-handling tasks such as PCR setup, nucleic acid extraction, ELISA assays, and next-generation sequencing sample preparation.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.